GSK's Cabenuva maintains continuous viral suppression in 81% of patients in real-world study

By Public Technologies
  • GSK-majority-owned ViiV Healthcare announced five-year US real-world study results supporting Cabenuva’s sustained effectiveness as a long-acting HIV treatment.
  • The OPERA study followed 6,955 adults switching from daily oral treatment; most maintained viral suppression and remained on Cabenuva.
  • Confirmed treatment failure was uncommon, supporting the injectable regimen’s role as an alternative to daily oral therapy.
  • Results will be presented at IDWeek 2026 in Washington, D.C., October 21-24.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210901BIZWIRE_USPR_____20261019_BW882869) on October 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.